Pulmonology · Medical Literature
Accurate Identification and Intervention System Construction of Treatable Traits in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Study.
Abstract
Considerable heterogeneity exists in patients experiencing acute exacerbation of chronic obstructive pulmonary disease (AECOPD) concerning etiology, clinical manifestations, phenotypic features, comorbidities, and treatment responsiveness. The concept of "treatable traits" is adapted to evaluate the clinical features of patients with chronic airway diseases from multiple dimensions and ultimately guiding precision treatment strategies. This prospective randomized controlled study mainly aims to evaluate the impact of accurate identification and intervention strategies guided by "treatable traits" on the prognosis of AECOPD patients. This prospective randomized controlled study will be performed in 6 centers in China, with a planned enrollment of 314 AECOPD participants. 314 participants will be randomly assigned to either the precision intervention group or the control group with a ratio of 1:1. During admission, participants in the precision intervention group will receive accurate identification and intervention based on "treatable traits", while patients in the control group receive conventional medical treatment as usual. Patients will be followed up at 6 and 12 months after discharge. Primary outcomes of the study include the incidence of total acute exacerbations and hospitalizations due to acute exacerbations during follow-up. Secondary outcomes involve changes in CAT scores and mMRC classification, and the occurrence of death during follow-up. By employing standardized, multi-dimensional baseline and follow-up assessments, the study seeks to develop a comprehensive framework of treatable traits encompassing pulmonary, extrapulmonary, and socio-behavioral domains for AECOPD. It will further evaluate the prognostic impact of precision interventions tailored to these treatable traits in AECOPD patients for the first time.
Clinical relevance
AECOPD carries substantial morbidity and mortality, yet management remains largely uniform despite marked heterogeneity in etiology, phenotype, comorbidities, and treatment responsiveness across patients. This protocol addresses the critical gap between a 'one-size-fits-all' approach and the biological reality of AECOPD by operationalizing the 'treatable traits' framework—a precision medicine paradigm previously applied to stable chronic airway disease—in the acute exacerbation setting. With repeated exacerbations driving disease progression and healthcare utilization, a validated precision intervention strategy could meaningfully alter the natural history of COPD for a high-burden patient population.
Key findings
1. Study design: Prospective, multicenter (6 centers in China), 1:1 randomized controlled trial with a planned enrollment of 314 AECOPD participants, providing adequate power for the primary endpoint analysis. 2. Intervention arm: Participants in the precision intervention group undergo systematic, multi-dimensional identification of 'treatable traits' at admission—spanning pulmonary, extrapulmonary, and socio-behavioral domains—with targeted interventions guided by identified traits, versus standard-of-care in the control arm. 3. Primary outcomes: Incidence of total acute exacerbations and rate of hospitalization attributable to acute exacerbations over a 12-month post-discharge follow-up period (assessed at 6 and 12 months). 4. Secondary outcomes: Change from baseline in COPD Assessment Test (CAT) score and modified Medical Research Council (mMRC) dyspnea classification, as well as all-cause mortality during follow-up. 5. Framework development: The study is explicitly designed to construct and validate a comprehensive treatable traits framework for AECOPD—the first RCT to prospectively evaluate prognostic impact of precision interventions tailored to treatable traits in this specific population. 6. NOTE: As this is a published protocol, no efficacy results, effect sizes, confidence intervals, p-values, or NNT/NNH are yet available; quantitative outcomes data await trial completion.
Practice implications
Clinicians managing AECOPD should anticipate a forthcoming evidence base supporting systematic, multi-dimensional phenotyping at the time of hospitalization—encompassing pulmonary (e.g., eosinophilic inflammation, bronchiectasis), extrapulmonary (e.g., cardiovascular comorbidities, metabolic dysfunction), and behavioral/social domains—to guide individualized rather than uniform treatment decisions. If the trial confirms superiority of the treatable traits-guided approach, adoption of structured phenotyping protocols at admission would be warranted, with targeted therapies (e.g., corticosteroid dosing calibrated to eosinophil count, directed antimicrobial selection, comorbidity co-management) replacing empiric regimens. In the interim, specialist teams should familiarize themselves with the treatable traits framework as a conceptual model and consider incorporating available precision tools—such as blood eosinophil counts and validated comorbidity screening—into current AECOPD admission workflows.